Clinical Trial Update: ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab [Phase 3]

View source ↗

Summary

Phase 3 trial update for canakinumab in first-line use for systemic juvenile idiopathic arthritis (SJIA) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis (SJIA) | Phase 3 | Status: COMPLETED | Results posted: 2019-07-09